Ionis Pharmaceuticals Inc (NASDAQ: IONS) has reported a loss for its second fiscal quarter (ending June 30) of $-0.45 versus a loss $-0.60 for the same period a year ago. For the latest four quarters through June 30, E.P.S. were $-2.52 compared to $-2.17 a year ago.
Recent Price Action
On 8/1/24, Ionis Pharmaceuticals Inc (NASDAQ: IONS) stock enjoyed a large increase of 3.8%, closing at $51.32. Trading volume in this advance was normal. The stock has been weak relative to the market over the last nine months but has risen 1.1% during the last week.
Current PriceTarget Research Rating
IONS is expected to continue to be a modest Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Ionis Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Ionis Pharmaceuticals has a poor Power Rating of 19 and a very low Appreciation Score of 3, and the Lowest Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment